BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

...homolog 1 BDNF - Brain-derived neurotrophic factor DCC - Deleted in colorectal carcinoma GSK3 - Glycogen synthase...
...B.V. Quark Pharmaceuticals Inc. Acousia Therapeutics GmbH Sound Pharmaceuticals Inc. Otologic Pharmaceutics Inc. Brain-derived neurotrophic factor (BDNF) Atonal homolog 1 (ATOH1) (HATH1) Glycogen synthase...
BioCentury | Aug 1, 2019
Product Development

NeuBase takes antisense oligos to more targets in more places

...Wave Life Sciences Ltd. (NASDAQ:WVE), Cambridge, Mass. Targets DMPK - Dystrophia myotonica-protein kinase GSK3B - Glycogen synthase...
BioCentury | May 17, 2019
Financial News

Actuate gets $21.7M to expand clinical testing of lead candidate

...Tech Coast Angels and existing investor Bios Partners. While several companies are developing inhibitors against glycogen synthase...
...million series A in 2017 from Bios Partners and IllinoisVENTURES. Elizabeth S. Eaton, Staff Writer 9-ING-41 Actuate Therapeutics Inc. Glycogen synthase...
BioCentury | May 14, 2019
Distillery Therapeutics

GSK3A inhibition restores asparaginase sensitivity in resistant ALL, AML

...alone. Next steps could include testing GSK3A inhibitors in mouse models of asparaginase-resistant AML. TARGET/MARKER/PATHWAY: Glycogen synthase...
...Cambridge, Mass. email: alejandro.gutierrez@childrens.harvard.edu Sandi Wong Boston Children's Hospital Broad Institute of MIT and Harvard Dana-Farber Cancer Institute Harvard Medical School Glycogen synthase...
BioCentury | Mar 5, 2019
Distillery Techniques

Vascularized kidney organoids for modeling renal disease

...steps: culturing human pluripotent stem cells with fibroblast growth factor 9 (FGF9; GAF) and a glycogen synthase...
BioCentury | Dec 11, 2018
Distillery Therapeutics

Cancer

...the GSK3 inhibitor tideglusib in Phase II testing for myotonic dystrophy type 1 (DM1). TARGET/MARKER/PATHWAY: Glycogen synthase...
...Center and Research Institute, Tampa, Fla. email: said.sebti@moffitt.org Claire Quang H. Lee Moffitt Cancer Center and Research Institute Glycogen synthase...
BioCentury | Nov 9, 2018
Tools & Techniques

HitGen’s DNA for small molecules

...deal in which the target was disclosed; the companies partnered to discover allosteric inhibitors of glycogen synthase...
BioCentury | Oct 18, 2018
Distillery Therapeutics

Neurology

...with fibroblast growth factors and inhibitors of bone morphogenic protein, transforming growth factor β (TGFβ), glycogen synthase...
BioCentury | Aug 23, 2018
Distillery Therapeutics

Neurology

...263, a GSK3B inhibitor, in preclinical testing to treat AD and amyotrophic lateral sclerosis. TARGET/MARKER/PATHWAY: Glycogen synthase...
...Maria Laura Bolognesi, University of Bologna, Bologna, Italy email: marialaura.bolognesi@unibo.it Claire Quang University of Bologna Alma Mater Studiorum Glycogen synthase...
BioCentury | May 16, 2018
Distillery Therapeutics

Neurology

...and solid tumors and has the compound in preclinical testing to treat neuroendocrine tumors. TARGET/MARKER/PATHWAY: Glycogen synthase...
...Spain email: sguil@idibell.cat CONTACT: Manel Esteller, same affiliation as above email: mesteller@idibell.cat Claire Quang Bellvitge Biomedical Research Institute Glycogen synthase...
Items per page:
1 - 10 of 99